Skip to main content
Clinical Trials/TCTR20220510001
TCTR20220510001
Completed
Phase 4

The effects of adding intravenous midazolam into a dual postoperative nausea and vomiting regimen in patients undergoing breast surgery: a pragmatic randomized controlled trial

Faculty of Medicine, Chulalongkorn university0 sites298 target enrollmentMay 10, 2022

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
female patients undergoing breast surgery
Sponsor
Faculty of Medicine, Chulalongkorn university
Enrollment
298
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 10, 2022
End Date
July 28, 2023
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Female age 18\-65 years old , 2\.ASA physical status I\-III, 3\. BMI 18 \- 40 kg/m2

Exclusion Criteria

  • 1\. Patient's refusal ,2\. Allergic or contraindicate to drug in this trial ,3\. Chronic opioid use ( \>3 mo) , 4\.Chronic benzodiazepine use , 5\.Antipsychotic use, 6\.previous anticancer chemotherapy within 1 month, 6\. Pregnancy ,7\.OSA patient ,8\. Poor controlled DM (HbA1C\>9\) , 9\. Hx receiving antiemetic within 24 hr

Outcomes

Primary Outcomes

Not specified

Similar Trials